Rodin Therapeutics: Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases

Rodin Therapeutics today announced the initiation of a Phase 1 clinical trial of the companys lead candidate RDN929 a potent and selective HDACCoREST inhibitor. The compound is designed to treat synaptopathies a group of over ...